Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance to develop next-generation gene therapies for Duchenne muscular dystrophy (DMD).
Collaboration Focus
Gene Cradle, which initiated its DMD gene therapy project in 2021, has focused on optimizing Dystrophin proteins and regulatory elements. The company has designed Smart Dystrophin, which has shown comprehensive biological activity in various DMD model animals, improving disease outcomes.
Byongen Therapeutics contributes its DynEvoLib capsid discovery platform, which has developed novel AAV capsids with muscle-targeting properties. These capsids offer significant advantages in transgenic expression and safety, providing an efficient delivery tool for DMD gene therapy.-Fineline Info & Tech
Leave a Reply